ENGEL Group has closed the 2024/25 financial year with a turnover of approximately EUR 1.5 billion. Despite a continued decline in market conditions, the injection molding machine manufacturer held its ground against European competitors and continued to expand its market share, driven by innovation and targeted regional strategies.

Although revenue fell by nearly 10% compared to the previous year, ENGEL has demonstrated its resilience. The past financial year was marked by reduced investment activity and a significant drop in incoming orders across all areas of industry. ENGEL systematically increased its market share in multiple sectors and regions.

To address the global decline in demand, ENGEL is pursuing a triad strategy focused on Europe, the Americas and Asia. This approach is supported by independent hubs with sales, sales support, production and after sales, strengthening local presence and technological innovation.

While the automotive sector continues to face structural uncertainties, interest is growing in solutions for lightweight construction and alternative materials. In technical injection molding, ENGEL was able to strengthen its market position through expertise in applications technology, despite the overall market trend.

The Packaging division proved to be much more resilient, benefiting from an increase in demand. The Medical division remained stable, with sustained interest in specific applications such as auto-injectors helping to offset a slight overall decline.

"We have learnt to remain capable of action during crises - and once again proven that ENGEL can act reliably and with foresight even under difficult conditions," said Stefan Engleder, CEO of ENGEL Group.

ENGEL Group has closed the 2024/25 financial year with a turnover of approximately EUR 1.5 billion. Despite a continued decline in market conditions, the injection molding machine manufacturer held its ground against European competitors and continued to expand its market share, driven by innovation and targeted regional strategies.

Although revenue fell by nearly 10% compared to the previous year, ENGEL has demonstrated its resilience. The past financial year was marked by reduced investment activity and a significant drop in incoming orders across all areas of industry. ENGEL systematically increased its market share in multiple sectors and regions.

To address the global decline in demand, ENGEL is pursuing a triad strategy focused on Europe, the Americas and Asia. This approach is supported by independent hubs with sales, sales support, production and after sales, strengthening local presence and technological innovation.

While the automotive sector continues to face structural uncertainties, interest is growing in solutions for lightweight construction and alternative materials. In technical injection molding, ENGEL was able to strengthen its market position through expertise in applications technology, despite the overall market trend.

The Packaging division proved to be much more resilient, benefiting from an increase in demand. The Medical division remained stable, with sustained interest in specific applications such as auto-injectors helping to offset a slight overall decline.

"We have learnt to remain capable of action during crises - and once again proven that ENGEL can act reliably and with foresight even under difficult conditions," said Stefan Engleder, CEO of ENGEL Group.